Fusion Fuel Green Hosts First Quarter 2024 Investor Update
SABUGO, Portugal, June 05, 2024 (GLOBE NEWSWIRE) — Fusion Fuel Green plc (NASDAQ: HTOO) (“Fusion Fuel”), an emerging leader in […]
Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2024 Results
LAKEWOOD, Colo., June 05, 2024 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture […]
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market […]
Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated […]
Immutep successfully completes institutional placement and institutional component of entitlement offer
Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) — Immutep Limited ACN 009 237 889 (ASX: IMM, NASDAQ: IMMP) (Immutep or […]
Fusion Fuel Secures 100 kW Electrolyzer Contract for Hospital in Iberia
SABUGO, Portugal, June 05, 2024 (GLOBE NEWSWIRE) — Fusion Fuel (NASDAQ: HTOO) announced today that it has signed a 100 […]
UP Fintech Holding Limited Reports Unaudited First Quarter 2024 Financial Results
SINGAPORE, June 05, 2024 (GLOBE NEWSWIRE) — UP Fintech Holding Limited (NASDAQ: TIGR) (“UP Fintech” or the “Company”), a leading […]
VIS and NXP to Establish a Joint Venture to Build and Operate a 300mm Fab
HSINCHU, Taiwan and EINDHOVEN, The Netherlands, June 05, 2024 (GLOBE NEWSWIRE) — Vanguard International Semiconductor Corporation (“VIS”, TPEx 5347) and […]
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical […]
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing […]
